Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.

Daraxonrasib significantly improves overall survival and progression-free survival in previously treated metastatic pancreatic ductal adenocarcinoma, with median overall survival of 13.2 months versus 6.6 months for chemotherapy.

• Why it matters: Metastatic pancreatic ductal adenocarcinoma has limited treatment options and poor prognosis, especially after initial therapies fail, highlighting the need for more effective targeted treatments.
• What they did: A phase 3 trial randomized 500 patients, predominantly with RAS G12 mutations, to receive daraxonrasib or chemotherapy, assessing survival outcomes, response rates, and safety.
• The result: Daraxonrasib reduced the risk of death and disease progression compared to chemotherapy, enabling longer survival and better disease control, with fewer treatment discontinuations due to adverse events.